/

RDHL

Redhill Biopharma Ltd.Closed

0.5150−0.02 −3.47%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.5020 −2.52%

Open

0.5145

Prev close

0.5335

Day range

0.50000.5334

52-week range

0.43502.14

Volume

80.27K0.04×

Mkt cap

4.58M

P/E ttm

—

Fwd P/E

17.17

EPS ttm

0.000000

Div yield

0.00%

Earnings

—

From 52w high

−75.93%

Price Chart

Yahoo Finance · delayed

RDHLOct 13, 2026O 0.5150H 0.5330L 0.5000C 0.5150−0.0180 (−3.38%)Vol 81.60K

SMA 500.5971
SMA 2000.8597

1Y change −68.40% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RDHL Redhill Biopharma Ltd. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +6.40%
1 month: −20.16%
3 months: −30.31%
6 months: −36.42%
Year to date: −50.00%
1 year: −68.40%

Valuation & ownership

Market cap: 4.58M
Enterprise value: −1.46M
P/E (ttm): —
Forward P/E: 17.17
PEG ratio: —
Price / book: 0.61
Price / sales (ttm): —
EV / EBITDA: 0.18
EPS (ttm): 0.000000
EPS (forward): 0.0300
Beta (5y monthly): 4.90
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 8.89M
Float: 4.20M
Short % of float: 2.40%
Short ratio (days): 0.04
Held by insiders: 0.00%
Held by institutions: 3.48%
Avg volume (3m): 2.09M
50-day average: 0.5998
200-day average: 0.8629
52-week change: −68.40%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 44.5
vs 50-day SMA: −13.75%
vs 200-day SMA: −40.10%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 11.76%
Realised vol (20d, ann.): 92.5%
From 52-week high: −75.93%
From 52-week low: +18.39%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 0
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Redhill Biopharma Ltd.

Yahoo Finance profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 13
Headquarters: Tel Aviv-Yafo, Israel
Website: redhillbio.com
Officers: Mr. Dror Ben-Asher Co-Founder, Chairman & CEO
Mr. Razi Ingber

SEAS

Seasonality · RDHL

2013–2026 · monthly returns

Strongest month Nov +16.75%Weakest month Dec −10.32%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	18.4	-20.5	-23.2	46.3	-8.3	-15.5	-23.1	38.5	-46.7	7.3			−50.0%
2025	-4.8	-43.6	-20.1	-17.1	-18.8	8.4	-32.5	3.1	60.7	-40.1	-7.7	-14.2	−83.4%
2024	-60.3	6.2	-14.0	-18.7	6.3	-19.0	3.5	-11.5	2.8	-5.7	3.2	-26.9	−83.0%
2023	55.7	4.1	-55.0	-40.6	-4.5	-48.3	6.7	-31.4	-41.9	-12.5	348.4	-27.0	−73.9%
2022	1.9	-16.7	15.1	-32.9	-33.7	-22.3	0.0	3.3	-44.2	38.6	-48.3	-61.1	−94.6%
2021	4.2	12.8	-22.9	-6.8	6.3	-5.1	-6.4	56.8	-54.7	18.8	-46.3	-11.6	−68.1%
2020	-12.9	-21.9	9.7	58.5	-0.8	-5.9	18.4	4.2	23.7	-18.2	5.7	-8.6	+33.1%
2019	49.5	-8.0	8.8	-5.4	-5.7	-12.3	1.8	14.5	-7.1	-4.8	2.2	-11.4	+9.4%
2018	21.0	3.5	-20.0	-5.8	47.2	19.5	-8.9	-3.7	18.0	-10.6	6.6	-34.0	+8.0%
2017	-6.6	-1.8	0.0	4.9	-6.8	-8.1	14.0	-12.3	25.4	-17.5	-43.5	2.0	−50.9%
2016	-23.1	-2.1	26.4	4.7	-14.6	-0.8	20.8	14.0	-7.2	-14.2	-8.5	-4.1	−18.8%
2015	12.7	-5.7	2.7	-0.3	12.0	8.4	-15.8	-13.1	0.3	-12.4	14.9	-0.8	−3.4%
2014	6.4	13.5	-1.1	1.1	16.8	5.2	-17.2	2.6	-11.3	-29.8	-4.8	51.5	+13.0%
2013		-21.0	2.3	-8.6	6.5	-3.3	-1.1	2.4	2.3	2.4	-4.3	12.2	−13.2%

INSD

Insider Activity · RDHL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

58.93M shares

Sells, 6 months

29.87M shares

Net shares

+29.06M

Net change in insider shares

−100.00%

Date	Insider	Transaction	Shares	Value
Jul 9, 2026	Raday GileadChief Operating Officer	Sale at price 0.70 per share.	14.13M	$9.82M
Jul 9, 2026	Raday GileadChief Operating Officer	Conversion of Exercise of derivative security at price 0.70 per share.	28.15M	$19.56M
Apr 5, 2026	Raday GileadChief Operating Officer	Sale at price 0.83 per share.	15.74M	$13.05M
Apr 5, 2026	Raday GileadChief Operating Officer	Conversion of Exercise of derivative security at price 0.83 per share.	30.78M	$25.52M

RDHL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RDHL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Redhill Biopharma Ltd.

Seasonality · RDHL

Insider Activity · RDHL

Congress Trades · RDHL

Investors Holding RDHL

Investors Holding RDHL

Congress Trades · RDHL

Insider Activity · RDHL

Seasonality · RDHL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Redhill Biopharma Ltd.

Earnings & Dividends

News